Gilead's Lenacapavir Launches in South Africa, Expanding HIV Prevention Access
Event summary
- Gilead's long-acting HIV prevention drug lenacapavir launched in South Africa, a country with 7.8 million people living with HIV and 170,000 new infections annually.
- The launch is supported by partnerships with the Government of South Africa, the Global Fund, and PEPFAR, with initial supply provided at no profit to Gilead.
- Gilead has established royalty-free voluntary license agreements with six manufacturers to enable generic supply across 120 low- and lower-middle-income countries.
- Phase 3 PURPOSE 1 and PURPOSE 2 trials included many sites in South Africa, reflecting Gilead's commitment to developing solutions in the most affected communities.
The big picture
Gilead's strategic focus on expanding access to lenacapavir aligns with global efforts to end HIV as a public health threat. The launch in South Africa, a high-burden country, underscores the importance of public-private partnerships in addressing healthcare disparities. The company's commitment to royalty-free licensing and local manufacturing reflects a broader industry trend toward sustainable access models in low- and middle-income countries.
What we're watching
- Market Penetration
- The pace at which lenacapavir adoption will scale in South Africa and other high-burden regions, given the competitive landscape and existing prevention options.
- Supply Chain Dynamics
- Whether Gilead's voluntary licensing agreements and local manufacturing pathways will ensure long-term supply resilience and affordability.
- Regulatory Approvals
- How quickly lenacapavir will gain regulatory approvals in additional countries, accelerating its global rollout and impact on HIV prevention.
Related topics